FDA Setback Weighs on Cancer Immunotherapy Market Outlook

Published: November 16, 2026

FDA Setback Weighs on Cancer Immunotherapy Market Outlook

Akeso Shares Fall as Much as 31.8% After FDA Declines to Approve Summit’s Ivonescimab Lung Cancer Drug

HONG KONG, China — November 16, 2026 — Shares of Akeso Inc. fell as much as 31.8% in Hong Kong on Monday after the U.S. Food and Drug Administration (FDA) declined to approve ivonescimab, a lung cancer drug from Summit Therapeutics. The development carries implications for the Cancer Immunotherapy Market, particularly for cross-border oncology development programmes.

Akeso’s Hong Kong-listed stock (9926.HK) touched HK$56.1, its lowest level since February 13, 2025. It later pared losses to a decline of 24.2%, on course for its largest daily percentage drop since April 7, 2025, in a fourth consecutive session of declines. It was the steepest percentage faller on the Hang Seng Biotech index, which fell 2.7%.

The FDA refused to approve the drug on Sunday, a setback for efforts to widen treatment options for patients whose cancer progressed after earlier therapies. The agency judged that the survival benefit did not justify authorization. Summit acquired rights to ivonescimab in the United States, Canada, Europe and Japan from Akeso in 2022 under a deal valued at up to USD 5 billion, while Akeso retained rights in China and other markets.

Akeso’s shares have lost 44.8% year to date, against a 6.9% decline in the Hang Seng Index. The global cancer immunotherapy market was valued at USD 110.21 billion in 2023 and is predicted to reach USD 227.45 billion by 2030, at a CAGR of 10.9% from 2024 to 2030, according to Next Move Strategy Consulting.

Key Highlights:

  • The FDA declined on Sunday to approve ivonescimab, concluding that the survival benefit did not justify authorization.

  • Akeso fell as much as 31.8% to HK$56.1, its lowest since February 13, 2025, and led declines on the Hang Seng Biotech index.

  • Summit’s 2022 licensing agreement, valued at up to USD 5 billion, covers the United States, Canada, Europe and Japan, while Akeso retains China and other markets.

  • Akeso’s shares are down 44.8% year to date, compared with a 6.9% decline in the Hang Seng Index.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, the cancer immunotherapy market is defined by investment in research and development, thorough clinical trials and a strong lineup of new products. NMSC analysts note that North America holds the dominant market share, while Asia-Pacific shows a steady rise through the forecast period.

NMSC analysts also observe that lung cancer remains one of the principal application segments. The high cost of therapies is a key restraint, while newer immunotherapies, including checkpoint inhibitors, are expected to create growth opportunities.

Industry Outlook:

The FDA’s decision is likely to keep regulatory evidence standards, licensing structures and cross-border clinical-trial strategy at the centre of oncology investment discussions. Market participants will be watching how the outcome shapes sentiment toward biotechnology developers with partnered assets.

Over the longer term, NMSC projects the cancer immunotherapy market to reach USD 227.45 billion by 2030, supported by rising cancer incidence, an ageing population and continued research funding.

Source: Reuters (via Boursorama)

For More Information: Download FREE Sample on Cancer Immunotherapy Market Report 

Prepared By: Sanyukta Deb

About the Author

Sanyukta Deb Sanyukta Deb — Sanyukta Deb is Digital Marketing Team Lead at Next Move Strategy Consulting, where she has led content strategy and technical SEO for the firm's B2B market research publications for over 2 years. Her editorial process translates NextMSC's primary and secondary research — spanning technology, industrial, and consumer sectors — into commercial narratives, backed by search-intent, keyword, and competitive analysis. She brings 5 years of overall experience in digital marketing and content strategy.

About the Reviewer

Debashree Dey Debashree Dey — Debashree Dey is Assistant Manager at Next Move Strategy Consulting, where she supports cross-vertical market content and communications across diverse industries for 6 years. Her professional background includes senior content writing, communications, and published manuscript authorship, with experience developing audience-focused business narratives and maintaining clear, consistent messaging. Her role supports research-led content development and editorial quality across NextMSC publications.

Add Comment

Please Enter Full Name

Please Enter Valid Email ID

Please enter comment

Share with Peers

  • Facebook
  • Twitter
  • Linkedin
  • Whatsapp
  • Mail
Our Clients

This website uses cookies to ensure you get the best experience on our website. Learn more

✖